World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
107
Citations
54527
World Ranking
6143
National Ranking
3284

Overview

Daniel J. Wallace is affiliated with Cedars-Sinai Medical Center in the United States. Their research primarily focuses on Medicine, with significant work in Rheumatology, Immunology, Pathology and Forensic Medicine, Genetics, and Radiology, Nuclear Medicine and Imaging.

The scientist's main topics of study include Systemic Lupus Erythematosus Research, Atherosclerosis and Cardiovascular Diseases, Monoclonal and Polyclonal Antibodies Research, Lymphoma Diagnosis and Treatment, Systemic Sclerosis and Related Diseases, Chronic Lymphocytic Leukemia Research, and Cytokine Signaling Pathways and Interactions.

Recent published papers include:

  • Macrophage fumarate hydratase restrains mtRNA-mediated interferon production, 2023, Nature
  • Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I), 2023, The Lancet
  • Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort, 2021, Lara D. Veeken
  • Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, 2021, Annals of the Rheumatic Diseases
  • Genome-wide association study identifies Sjögren's risk loci with functional implications in immune and glandular cells, 2022, Nature Communications

Frequent co-authors include Rosalind Ramsey-Goldman, Kenneth Kalunian, Cynthia Aranow, Ann E. Clarke, and Diane L. Kamen. These collaborative partnerships have contributed to numerous studies across the related fields.

The scientist's work is frequently published in venues such as Annals of the Rheumatic Diseases, UNC Libraries, Lupus Science & Medicine, Arthritis & Rheumatology, and Arthritis Care & Research.

Best Publications

  • Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

    Michelle Petri;Ana Maria Orbai;Graciela S. Alarcõn;Caroline Gordon

  • 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

    Martin Aringer;Karen Costenbader;David Daikh;Ralph Brinks

  • The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes

    Matthew H. Liang;Michael Corzillius;Sang Cheol Bae;Robert A. Lew

  • A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

    Richard Furie;Michelle Petri;Omid Zamani;Ricard Cervera

  • American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

    Bevra H. Hahn;Maureen A. McMahon;Alan Wilkinson;W. Dean Wallace

  • Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial

    Joan T. Merrill;C. Michael Neuwelt;Daniel J. Wallace;Joseph C. Shanahan

  • Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

    Ellen M. Ginzler;Mary Anne Dooley;Cynthia Aranow;Mimi Y. Kim

  • Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

    Christian E. Antoni;Arthur Kavanaugh;Bruce Kirkham;Zuhre Tutuncu

  • A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.

    Dimitrios T. Boumpas;Richard Furie;Susan Manzi;Gabor G. Illei

  • Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis.

    M Linker-Israeli;R J Deans;D J Wallace;J Prehn

  • Dubois' Lupus Erythematosus

    Daniel J. Wallace

  • The frequency and outcome of lupus nephritis: results from an international inception cohort study

    John G. Hanly;Aidan G. O'Keeffe;Li Su;Murray B. Urowitz

  • A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus

    Daniel J. Wallace;William Stohl;Richard A. Furie;Jeffrey R. Lisse

  • Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

    Ian N Bruce;Aidan G O'Keeffe;Vernon Farewell;John G Hanly

  • Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

    Daniel J Wallace;Richard A Furie;Yoshiya Tanaka;Kenneth C Kalunian

  • Proinflammatory high‐density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis

    Maureen McMahon;Jennifer Grossman;John FitzGerald;Erika Dahlin-Lee

  • Lupus erythematosus in the 1980s: a survey of 570 patients.

    Moshe Pistiner;Daniel J. Wallace;Sharon Nessim;Allan L. Metzger

  • Novel Evidence-Based Systemic Lupus Erythematosus Responder Index

    Richard A. Furie;Michelle A. Petri;Daniel J. Wallace;Ellen M. Ginzler

  • Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.

    Daniel J Wallace;Kenneth Kalunian;Michelle A Petri;Vibeke Strand

  • Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.

    Maria Dall'Era;Eliza Chakravarty;Daniel Wallace;Mark Genovese

Frequent Co-Authors

Michael H. Weisman
Michael H. Weisman Cedars-Sinai Medical Center
Michelle Petri
Michelle Petri Johns Hopkins University School of Medicine
Rosalind Ramsey-Goldman
Rosalind Ramsey-Goldman Northwestern University
Joan T. Merrill
Joan T. Merrill Oklahoma Medical Research Foundation
Kenneth C. Kalunian
Kenneth C. Kalunian University of California, San Diego
Murray B. Urowitz
Murray B. Urowitz University of Toronto
Caroline Gordon
Caroline Gordon University of Birmingham
Ann E. Clarke
Ann E. Clarke University of Calgary
David A. Isenberg
David A. Isenberg University College London
Susan Manzi
Susan Manzi Allegheny Health Network

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

In addition to traditional medical education, there is growing interest in allied healthcare degrees that offer flexible, online, and accelerated options. If you’re seeking advanced nursing qualifications, consider exploring accelerated dnp programs online and dnp online programs. These options can enable you to earn a Doctor of Nursing Practice degree in less time, supporting a quicker pathway to leadership or specialized roles.

For those aiming to enter the workforce sooner, there are accelerated lpn program tracks that make it possible to become a Licensed Practical Nurse quickly and flexibly. If mental health is your focus, you may want to look into the fastest psych np program options, letting you earn a specialized MSN and step into critical psychiatric nurse practitioner roles.

These online degrees can be appealing for working professionals, career changers, or anyone wanting to advance rapidly. Program length, admission requirements, and career prospects should be considered carefully before choosing a pathway.

Best Scientists Citing Daniel J. Wallace

Trending Scientists